Uncoupling protein-2 gene polymorphisms are associated with obesity in Hungarian children

K Csernus1, G Pauler, E Erhardt

  • 1Department of Pediatrics, Medical Faculty, University of Pecs, Pecs, Hungary. cs-kata@freemail.hu

Insights

Genetic variations in the uncoupling protein 2 (UCP-2) gene are linked to childhood obesity risk. Specific UCP-2 gene polymorphisms may influence a child's propensity towards being overweight or obese.

Area of Science:

  • Genetics
  • Pediatrics
  • Metabolism

Background:

  • Childhood obesity is a growing public health concern.
  • Genetic factors play a role in energy metabolism and obesity development.
  • Identifying gene polymorphisms associated with obesity can inform prevention strategies.

Purpose of the Study:

  • To investigate the frequency of common gene polymorphisms related to energy metabolism in children.
  • To determine if these polymorphisms affect the risk of childhood obesity in a Hungarian cohort.

Main Methods:

  • Genotyping was performed on 1,346 children (6-17 years old), including 709 overweight/obese and 637 normal weight.
  • Polymorphisms analyzed included those in the β3-adrenoreceptor, uncoupling protein (UCP)-1, UCP-2, UCP-3, and peroxisome proliferator-activated receptor-γ genes.
  • Statistical analysis, including multivariate regression, was used to assess associations with obesity risk.

Main Results:

  • The UCP-2 -866 A variant was associated with a reduced odds ratio for obesity.
  • Conversely, UCP-2 exon 8 insertion allele carriers had an increased odds ratio for obesity.
  • No significant associations were found for other examined gene polymorphisms.

Conclusions:

  • Common polymorphisms within the UCP-2 gene appear to influence the susceptibility to overweight and obesity in Hungarian children.
  • These findings highlight the potential role of UCP-2 gene variants in pediatric obesity.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Human Genetics01:28

Human Genetics

Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Lethal Alleles02:41

Lethal Alleles

Agouti: A Lethal Allele
Lucien Cuénot discovered lethal alleles in 1905 while studying the inheritance of coat color in mice. The agouti gene is responsible for the color of the coat in mice. This gene codes for an agouti-signaling protein, which is responsible for melanin distribution in mammals. The wild-type allele gives rise to gray-brown coat color in mice, while the mutant allele gives rise to yellow coat color. In addition to coat color, the agouti gene is associated with the yellow...